Evidence map›Paper›PMID 24323912›Full record

ReviewThe Journal of endocrinology2014

Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.

L van Bloemendaal, J S Ten Kulve, S E la Fleur, R G Ijzerman, M Diamant

3 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in The Journal of endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 146 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 9 pooled it
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03361098 phase4completedstarted 2017, after this paper: background citation

Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients

Ran2017Enrolled65Registered outcomes18Posted comparisons0ConditionsObesity, Type 2 Diabetes MellitusArmsDapagliflozin 10mg, exenatide, placebo dapagliflozin, placebo exenatide
PMID 26769912PMID 27651331PMID 24463454PMID 20423700PMID 28869249PMID 28345814PMID 26815786PMID 26672638PMID 26403227PMID 26385462PMID 26331843PMID 26180105other papers from this trial
Open the trial in the graph
NCT06827002 phase1 / phase2active not recruitingstarted 2023, after this paper: background citation

Cissus Quadrangularis (CQR-300®) and Dichrostachys Glomerata (Dyglomera®) Extracts Increase GLP-1 Levels and Inhibit Dipeptidyl Phosphate-4 Activity in Healthy Overweight and Obese Adults

Ran2023Enrolled248Registered outcomes8Posted comparisons0ConditionsAppetite Regulation, Obesity and OverweightArmsCissus quadrangularia, Dextrin, Dichrostachys glomerata, Semaglutide (Rybelsus®)
PMID 15655721PMID 23622135PMID 26177483PMID 26288659PMID 27659407PMID 28450900PMID 4337382other papers from this trial
Open the trial in the graph
NCT03878706 recruitingnot on this mapstarted 2017, after this paper: background citation

The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk

Typeobservational_patient_registrySponsorUniversity of AthensRan2017 to 2027Enrolled240ConditionsDiabetes Mellitus, Type 2
3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 9 syntheses or guidelines pooled it, 300 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Effects ofMedicina (Kaunas, Lithuania) · 2025
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Review
  19. Article
  20. Article

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

L van BloemendaalDiabetes Centre, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands Department of Endocrinology and Metabolism, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
J S Ten Kulve
S E la Fleur
R G Ijzerman
M Diamant
University of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The delivery of nutrients to the gastrointestinal tract after food ingestion activates the secretion of several gut-derived mediators, including the incretin hormone glucagon-like peptide 1 (GLP-1). GLP-1 receptor agonists (GLP-1RA), such as exenatide and liraglutide, are currently employed successfully in the treatment of patients with type 2 diabetes mellitus. GLP-1RA improve glycaemic control and stimulate satiety, leading to reductions in food intake and body weight. Besides gastric distension and peripheral vagal nerve activation, GLP-1RA induce satiety by influencing brain regions involved in the regulation of feeding, and several routes of action have been proposed. This review summarises the evidence for a physiological role of GLP-1 in the central regulation of feeding behaviour and the different routes of action involved. Also, we provide an overview of presently available data on pharmacological stimulation of GLP-1 pathways leading to alterations in CNS activity, reductions in food intake and weight loss.

Indexed as

AnimalsAppetiteBody WeightCentral Nervous SystemDiabetes Mellitus, Type 2Glucagon-Like Peptide 1HumansGlucagon-Like Peptide 1CNSfeeding behaviourglucagon-like peptide 1obesitytype 2 diabetes

Identifiers

PMID24323912
OpenAlexW2017810555

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.